Cellular Pharmacokinetics and Pharmacodynamics of the Glycopeptide Antibiotic Oritavancin (LY333328) in a Model of J774 Mouse Macrophages
Open Access
- 1 August 2004
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 48 (8) , 2853-2860
- https://doi.org/10.1128/aac.48.8.2853-2860.2004
Abstract
The intracellular pharmacokinetics and pharmacodynamics of oritavancin (LY333328) were studied in cultured cells. Oritavancin was avidly accumulated by J774 and THP-1 macrophages and rat fibroblasts and to a lesser extent by LLC-PK1 and Caco-2 cells. In J774 macrophages, the level of accumulation reached a plateau (at 370-fold the extracellular concentration) within 24 h and was partly defeated by a rise in serum protein levels. Efflux was incomplete (with a plateau at two-thirds of the original level at 6 h). In short-term kinetic studies, oritavancin uptake was linear for up to 4 h (as was the case for horseradish peroxidase and small latex beads, used as markers of the fluid phase and adsorptive endocytosis, respectively), which was in contrast to azithromycin and chloroquine uptake (which accumulate in cells by diffusion and segregation). The rates of clearance of oritavancin and latex beads were comparable (150 and 120 μl × mg of protein−1× h−1, respectively) and were approximately 200 times higher than that of horseradish peroxidase. Oritavancin accumulation was partially reduced by monensin but was unaffected by acidic pH (these conditions abolished chloroquine accumulation). Cell-associated oritavancin was found in lysosomal fractions after homogenization of J774 macrophages and fractionation by isopycnic centrifugation. Oritavancin was bactericidal against intracellularStaphylococcus aureus(phagolysosomal infection) but was unable to control the intracellular growth ofListeria monocytogenes(cytosolic infection), even though its cellular concentration largely exceeded the MIC (0.02 mg/liter) and minimal bactericidal concentration (2 mg/liter). We conclude that oritavancin enters cells by adsorptive endocytosis (favored by its lipophilic side chain and/or the presence of three protonatable amines), which drives it to lysosomes, where it exerts antibiotic activity.Keywords
This publication has 47 references indexed in Scilit:
- Glycopeptide AntibioticsDrugs, 2004
- Size-dependent internalization of particles via the pathways of clathrin- and caveolae-mediated endocytosisBiochemical Journal, 2004
- Influence of P-Glycoprotein Inhibitors on Accumulationof Macrolides in J774 MurineMacrophagesAntimicrobial Agents and Chemotherapy, 2003
- Azithromycin, a Lysosomotropic Antibiotic, Has Distinct Effects on Fluid-Phase and Receptor-Mediated Endocytosis, but Does Not Impair Phagocytosis in J774 MacrophagesExperimental Cell Research, 2002
- Azithromycin, a lysosomotropic antibiotic, impairs fluid-phase pinocytosis in cultured fibroblastsEuropean Journal of Cell Biology, 2001
- Modulation of Intracellular Growth ofListeria monocytogenesin Human Enterocyte Caco‐2 Cells by Interferon‐γ and Interleukin‐6: Role of Nitric Oxide and Cooperation with AntibioticsThe Journal of Infectious Diseases, 1999
- Beyond vancomycin: new therapies to meet the challenge of glycopeptide resistanceTrends in Microbiology, 1997
- Cellular Transport of DrugsClinical Infectious Diseases, 1994
- Suppression of penicillin-induced bacteriolysis of staphylococci by some anticoagulantsJournal of Antimicrobial Chemotherapy, 1987
- Perturbation of vesicular traffic with the carboxylic ionophore monensinCell, 1983